Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Selma Ugurel

Showing results (181-190 of 265) with videos related to

Pageof 27
Sort By:
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 3, 2022
S1 Guidelines for the Kaposi SarcomaStefan Esser, Helmut Schöfer, Christian Hoffmann, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 17, 2022
S1-Leitlinie: Kaposi-SarkomStefan Esser, Helmut Schöfer, Christian Hoffmann, et al.
European Journal of Cancer (Oxford, England : 1990)|March 18, 2020
Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019Selma Ugurel, Joachim Röhmel, Paolo A Ascierto, et al.
The British Journal of Dermatology|July 27, 2025
Avelumab plus cetuximab in patients with unresectable stage III or IV cutaneous squamous cell carcinoma - clinical activity and safety results from AliCe, a single-arm, multicentre phase 2 DeCOG trialJürgen C Becker, Anja H Gesierich, Ulrike Leiter, et al.
Cancers|May 14, 2022
Genetic and Clinical Characteristics of <i>ARID1A</i> Mutated Melanoma Reveal High Tumor Mutational Load without Implications on Patient SurvivalCarl Maximilian Thielmann, Johanna Matull, Sebastian Roth, et al.
International Journal of Cancer|March 15, 2026
Real-world effectiveness and safety with nivolumab plus ipilimumab or nivolumab alone in patients with or without melanoma brain metastasis: Results from the German noninterventional NICO studyRalf Gutzmer, Michael Weichenthal, Thomas Eigentler, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2021
Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology GroupImke Grimmelmann, Michael Momma, Lisa Zimmer, et al.
Journal for Immunotherapy of Cancer|September 24, 2025
Tertiary lymphoid structures in Merkel cell carcinoma facilitate naïve and central memory T-cell infiltration linked to immunotherapy responseNalini Srinivas, Ivelina Spassova, Kuan Cheok Lei, et al.
Frontiers in Immunology|January 1, 2026
Extracorporeal photopheresis as a therapeutic approach for treatment resistant immune-related adverse events in anti-PD-1-treated melanoma patientsCarl Maximilian Thielmann, Johanna Andrea Seier, Lisa Schielke, et al.
European Journal of Cancer (Oxford, England : 1990)|April 14, 2025
Clinical course of Merkel cell carcinoma: A DeCOG multicenter study of 1049 patientsGeorg C Lodde, Ulrike Leiter, Anja Gesierich, et al.
Pageof 27

Showing results (181-190 of 265) with videos related to

Sort By:
Pageof 27
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 3, 2022
S1 Guidelines for the Kaposi SarcomaStefan Esser, Helmut Schöfer, Christian Hoffmann, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 17, 2022
S1-Leitlinie: Kaposi-SarkomStefan Esser, Helmut Schöfer, Christian Hoffmann, et al.
European Journal of Cancer (Oxford, England : 1990)|March 18, 2020
Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019Selma Ugurel, Joachim Röhmel, Paolo A Ascierto, et al.
The British Journal of Dermatology|July 27, 2025
Avelumab plus cetuximab in patients with unresectable stage III or IV cutaneous squamous cell carcinoma - clinical activity and safety results from AliCe, a single-arm, multicentre phase 2 DeCOG trialJürgen C Becker, Anja H Gesierich, Ulrike Leiter, et al.
Cancers|May 14, 2022
Genetic and Clinical Characteristics of <i>ARID1A</i> Mutated Melanoma Reveal High Tumor Mutational Load without Implications on Patient SurvivalCarl Maximilian Thielmann, Johanna Matull, Sebastian Roth, et al.
International Journal of Cancer|March 15, 2026
Real-world effectiveness and safety with nivolumab plus ipilimumab or nivolumab alone in patients with or without melanoma brain metastasis: Results from the German noninterventional NICO studyRalf Gutzmer, Michael Weichenthal, Thomas Eigentler, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2021
Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology GroupImke Grimmelmann, Michael Momma, Lisa Zimmer, et al.
Journal for Immunotherapy of Cancer|September 24, 2025
Tertiary lymphoid structures in Merkel cell carcinoma facilitate naïve and central memory T-cell infiltration linked to immunotherapy responseNalini Srinivas, Ivelina Spassova, Kuan Cheok Lei, et al.
Frontiers in Immunology|January 1, 2026
Extracorporeal photopheresis as a therapeutic approach for treatment resistant immune-related adverse events in anti-PD-1-treated melanoma patientsCarl Maximilian Thielmann, Johanna Andrea Seier, Lisa Schielke, et al.
European Journal of Cancer (Oxford, England : 1990)|April 14, 2025
Clinical course of Merkel cell carcinoma: A DeCOG multicenter study of 1049 patientsGeorg C Lodde, Ulrike Leiter, Anja Gesierich, et al.
Pageof 27